Anticancer agents from diverse natural sources

Natural Product Communications

Volumn 9, Issue 11, 2014, Pages 1655-1669

  Khazir, Jabeena ^a   Riley, Darren L ^a   Pilcher, Lynne A ^a   De Maayer, Pieter ^a   Mir, Bilal Ahmad ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Cancer; Drugs; Endophytes; Marine Organisms; Natural products; Plant derived anticancer drugs

Indexed keywords

ANTINEOPLASTIC AGENT; BRENTUXIMAB VEDOTIN; BRYOSTATIN 1; CARFILZOMIB; CEMADOTIN; CYTARABINE; DEHYDRODIDEMNIN B; DIDEMNIN B; DOLASTATIN; DOLASTATIN 15; EPOXOMICIN; ERIBULIN; EVEROLIMUS; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GLEMBATUMUMAB VEDOTIN; ILLUDIN S; IROFULVEN; LURBINECTEDIN; NATURAL PRODUCT; PANOBINOSTAT; PLINABULIN; RAPAMYCIN; SALINOSPORAMIDE A; SOBLIDOTIN; THYMINE ARABINOSIDE; TRABECTEDIN; UNINDEXED DRUG; URACIL ARABINOSIDE; VORSETUZUMAB MAFODOTIN; BIOLOGICAL PRODUCT;

ENDOPHYTIC FUNGUS; HUMAN; MARINE SPECIES; MICROORGANISM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLANT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TERRESTRIAL SPECIES;

ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS;

EID: 84911206696     PISSN: 1934578X     EISSN: 15559475     Source Type: Journal    
DOI: 10.1177/1934578x1400901130     Document Type: Review

References (248)

1. Shah U, Shah R, Acharya S, Acharya N. (2013) Novel anticancer agents from plant sources.Chinese Journal of Natural Medicines, 11, 0016-0023.
2. Cragg GM, Newman DJ. (2005) Plants as a source of anti-cancer agents. Journal of Ethnopharmacology, 100, 72-79.
3. Khazir J, Mir BA, Mir SA, Don C. (2013) Natural products as lead compounds in drug discovery. Journal of Asian Natural Products Research, 15, 764-788.
4. Newman DJ, Cragg GM. (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. Journal of Natural Products, 75, 311-335.
5. Newman DJ, Cragg GM. (2007) Natural products as sources of new drugs over the last 25 years. Journal of Natural Products, 70, 1022-1037.
6. Joanne B, Murali D, William E, Nils L. (2011)To Market To Market, Annual Reports in Medicinal Chemistry, Chapter 26, Volume 46, Pages 433-602.
7. Cragg GM, Kingston DJ, Newman D J. (2012) Anticancer agents from natural products, Second Edition CRC Press, Pages 1-577.
8. Peter E, Silvio R, Ansgar S. (2008) Natural product-likeness score and its application for prioritization of compound libraries. Journal of Chemical Information and Modeling, 48, 68-74.
9. Susan LH, Jerry MC, James HD. (2010) Analysis of FDA-approved anti-Cancer agents in the NCI60 panel of human tumor cell lines. Molecular Cancer Therapeutics, 9, 1451-1460.
10. Anand C, Neetu S. (2011) Contribution of world health organization in the global acceptance of Ayurveda. Journal of Ayurveda Integrative Medicine, 2, 179-186.
11. Khazir J, Mir BA, Pilcher L, Riley DL. (2014) Role of plants in anticancer drug discovery. Phytochemistry letters, 7, 173-181.
12. Vinorelbine official FDA information. http://www.drugs.com/pro/vinorelbine.html
13. John S Ng. (2011) Vinflunine: review of a new vinca alkaloid and its potential role in oncology. Journal of Oncology Pharmacy Practice, 17, 209-224.
14. Marqibo. http://www.marqibo.com.
15. http://www.clinicaltrials.gov/ct2/show NCT00003882
16. Gelmon KA. (1994) The Taxoids: paclitaxel and docetaxel. Lancet, 344, 1267-1272.
17. Channing J P, Emmanuel SA. (2011) Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Design Development Therapy, 5, 117-124.
18. Abraxane improves survival among pancreatic cancer patients. http://www.medicalnewstoday.com/articles/255388.php.
19. Payne M, Ellis P, Dunlop D, Ranson M, Danson S, Schacter L, Talbot D. (2006) DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial. Journal of Thoracic Oncology, 1, 984-990.
20. http://www.clinicaltrials.gov/ct2/show NCT00249262
21. Robert F, Harper K, Ackerman J, Gupta S. (2010) A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer. Cancer Chemotherapy Pharmacology, 65, 227-234.
22. Diéras V, Limentani S, Romieu G, Tubiana-Hulin M, Lortholary A, Kaufman P, Girre V, Besenval M, Valero V. (2008) Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Annals of Oncology, 19, 1255-60.
23. http://www.clinicaltrials.gov/ct2/show NCT00054314.
24. Ramanathan RK, Picus J, Raftopoulos H, Bernard S, Lockhart AC, Frenette G, Macdonald J, Melin S, Berg D, Brescia F, Hochster H, Cohn A. (2008) A phase II study of Milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. Cancer Chemotherapy Pharmacology, 61, 453-458.
25. Fitzgerald DP, Emerson DL, Qian Y, Anwar T, Liewehr DJ, Steinberg SM, Silberman S, Palmieri D, Steeg PS. (2012) TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Molecular Cancer Therapeutics, 11, 1959-1967.
26. TPI 287 in Breast Cancer Metastatic to the Brain. http://www.clinicaltrials. gov/ct2/show/NCT01332630
27. Heath EI, Lorusso P, Ramalingam SS, Awada A, Egorin MJ, Besse-Hamer T, Cardoso F, Valdivieso M, Has T, Alland L, Zhou X, Belani CP. (2011) A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies. Investigational New Drugs, 29, 1426-1431.
28. Saif MW, Sarantopoulos J, Patnaik A, Tolcher AW, Takimoto C, Beeram M. (2011) Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 68, 1565-1573.
29. Clinical trials for Tesetaxel. http://clinicaltrialsfeeds.org/clinical-trials/results/term=Tesetaxel
30. Scott L, Soepenberg O, Verweij J, de Jonge M J, Th Planting AS, McGovern D, Principe P, Obach R, Twelves C. (2007) A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours. Annals of Oncology, 18, 569-575.
31. Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC). http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00080015
32. Zhu AX, Ready N, Clark JW, Safran H, Amato A, Salem N, Pace S, He X, Zvereva N, Lynch TJ, Ryan DP, Supko JG. (2009) Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors. Clinical Cancer Research, 15, 374-81.
33. Pecorelli S, Ray-Coquard I, Tredan O, Colombo N, Parma G, Tisi G, Katsaròs D, Lhommé C, Lissoni A A, Vermorken J B, Bois A Du, Poveda A, Frigerio L, Barbieri P, Carminati P, Brienza S, Guastalla J P. (2010) Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. Annals of Oncology, 21, 759-765.
34. Adil D, Nikola V, Barbara C, Jennifer D, Patricia S, Pamela M, Patricia U, Ronald CD, Elmer B, Zhenmei L, Frederick H, Daniel S. (2005) Phase II Trial of Karenitecin in Patients with Malignant Melanoma: Clinical and Translational Study. Clinical Cancer Research, 11, 3009-3016.
35. Study of Karenitecin (BNP1350) to Treat Malignant Melanoma. http://www.clinicaltrials.gov/ct2/show/NCT00062491
36. Farray D, Ahluwalia M S, Snyder J, Barnett G H, Cohen BH, Suh J H, Peereboom DM. (2006) Pre-irradiation 9-amino [20s] camptothecin (9-AC) in patients with newly diagnosed glioblastoma multiforme. Investigational New Drugs, 24, 177-180.
37. Trocóniz IF, Cendrós JM, Soto E, Pruñonosa J, Perez-Mayoral A, Peraire C, Principe P, Delavault P, Cvitkovic F, Lesimple T, Obach R. (2012) Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, Elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors. Cancer Chemotherapy Pharmacology, 70, 239-250.
38. Ajani JA, Takimoto C, Becerra CR, Silva A, Baez L, Cohn A, Major P, Kamida M, Feit K, De Jager R. (2005) A phase II clinical and pharmacokinetic study of intravenous Exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Investigational New Drugs, 23, 479-484.
39. Exatecan Mesylate in Treating Children with Relapsed or Refractory Rhabdomyosarcoma.http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00055939
40. Clark JW. (2006) Rubitecan. Expert Opinion Investigational Drugs, 15, 71-79.
41. Mross K, Hüttmann A, Herbst K, Hanauske AR, Schilling T, Manegold C, Burk K, Hossfeld DK. (1996) Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. Cancer Chemotherapy Pharmacology, 38, 217-224.
42. Sargent JM, Elgie AW, Williamson CJ, Hill BT. (2003) Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer. Anticancer Drugs, 14, 467-473.
43. Zhang Y, Trissel LA. (1999) Physical and chemical stability of etoposide phosphate solutions Journal of American Pharmaceutical Association (Wash), 39, 146-150.
44. Nathan P, Zweifel M, Padhani AR, Koh DM, Ng M, Collins DJ, Harris A, Carden C, Smythe J, Fisher N, Taylor NJ, Stirling JJ, Lu SP, Leach MO, Rustin GJ, Judson I. (2012) Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clinical Cancer Research, 18, 3428-3439.
45. Patterson DM, Zweifel M, Middleton MR, Price PM, Folkes LK, Stratford MR, Ross P, Halford S, Peters J, Balkissoon J, Chaplin DJ, Padhani AR, Rustin GJ. (2012) Phase I Clinical and Pharmacokinetic Evaluation of the Vascular Disrupting Agent OXi4503 in Patients with Advanced Solid. Clinical Cancer Research, 18, 1415-25.
46. Mullauer FB, Kessler JH, Medema JP. (2010) Betulinic acid, a natural compound with potent anticancer effects. Anti-cancer Drugs, 21, 215-227.
47. Sudhakar C, Sabitha P, Ping L, Satya P, Stephen S. (2011) Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and-independent downregulation of specificity proteins (Sp) transcription factors. BMC Cancer, 11, 371-382.
48. Shailendra K. (2012) Emerging role of berbamine as an anti-cancer agent in systemic malignancies besides chronic myeloid leukemia. Journal of Zhejiang University Science B, 13, 761-762.
49. Blanco E, Bey EA, Khemtong C, Yang SG, Setti-Guthi J, Chen H, Kessinger CW, Carnevale KA, Bornmann WG, Boothman DA, Gao J. (2010) Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Research, 70, 3896-3904.
50. Clinical Trial of ARQ 761 in Advanced Solid Tumors. http://www.clinicaltrials. gov/ct2/show/NCT01502800
51. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. (2004) Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clinical Cancer Research, 10, 6847-6854.
52. Curcumin clinical trial. http://csn.cancer.org/node/239333.
53. Shehzad A, Wahid F, Lee YS. (2010) Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch. Pharm (Weinheim), 343, 489-499.
54. Bhattacharyya B, Panda D, Gupta S, Banerjee M. (2008) Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin.Medicinal Research Reviews, 28, 155-183.
55. Jung YL, Hee SK, Yong-Sang S. (2012) Genistein as a Potential Anticancer Agent against Ovarian Cancer. Journal of Traditional Complement Medicine, 2, 96-104.
56. Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, House M, Busby JE, Hohl R, Bailey H. (2012) A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients.Cancer Preview Research (Phila), 5, 621-630.
57. Levis S, Strickman-Stein N, Ganjei-Azar P, Xu P, Doerge DR, Krischer J. (2011) Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial. Archives of Internal Medicine, 171, 1363-1369.
58. Daniel P, Darren JP, Wendy L, Mark SW, Shruti S, Katherin AF, Stefanie NV.(2012)5, 6-Dimethylxanthenone-4-acetic acid (DMXAA) activates Stimulator of Interferon Gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. Journal of Biological Chemistry, 287, 39776-39788.
59. Buchanan CM, Shih JH, Astin JW, Rewcastle GW, Flanagan JU, Crosier PS, Shepherd PR. (2012) DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular. Clinical Science (London), 122, 449-457.
60. Wenjun N, Jia Ji, Zunyan D, Audrey P, Amy JJ, Sunjoo A, Katherine LF, Thomas SL, James T D, Xiaobai L, David J, John CB, Wolfgang S, Michael RG, Mitch APA.(2010) Phelps. Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition. PLoS ONE, 5, e13792.
61. Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer. http://www.clinicaltrials.gov/ct2/show/NCT00016939
62. Yi-Ping Z, Xin-En H, Jie C, Yan-Yan Lu, Xue-Yan W, Jin L, Xia X, Jin X, Li-Hong, Y. (2012) Clinical Safety and Efficacy of Kanglaite(Coix Seed Oil) Injection Combined with Chemotherapy in Treating Patients with Gastric Cancer Asian Pacific Journal of Cancer Preview, 13, 5319-5321.
63. Safety and Efficacy of KanglaiteGelcaps in Prostate Cancer. http://www.clinicaltrials. gov/ct2/show/NCT01483586.
64. Lee CC, Lin CP, Lee YL, Wang GC, Cheng YC, Liu HE. (2010) Meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia. Leukemia and Lymphoma, 51, 897-905.
65. Simon M, Frank A, Pierra R, Susan H, David B, Michael M, Arun D. (2012) Cytotoxic effects of the novel isoflavone, phenoxodiol, on prostate cancer cell lines. Journal of Biosciences, 37, 73-84.
66. Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients with Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer. http://www.clinicaltrials.gov/ct2/show/NCT00091377.
67. Juergen F, Foell D M, Corinna G, Dieter K, Martin S. (2008) Staege Sensitivity of Hodgkin's Lymphoma Cell Lines to the Cell Cycle Inhibitor Roscovitine. Anti-cancer Research, 28, 887-894.
68. Clinical trials for Roscovitine http://clinicaltrialsfeeds.org/clinical-trials/results/intr=%22 Roscovitine%22.
69. Kim S, Hwang BY, Su BN, Chai H, Mi Q, Kinghorn AD, Wild R, Swanson SM. (2007) Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or-7. Anti-cancer Research, 27, 2175-2183.
70. Salvestrol Clinical Trials by Gerry Potter. http://goarticles.com/article/Salvestrol-Clinical-Trials/6405760/.
71. Khazir J, Singh PP, Doma MR, Syed S, Hyder I, Gousia C, Ajay M, Alam MS, Saxena AK, Arvinda S, Gupta BD, Kumar, HMS. (2013) Synthesis and anti-cancer activity of novel spiro-isoxazoline and-isoxazolidine derivatives of α-santonin. European Journal of Medicinal Chemistry, 63, 279-289.
72. Sources of Drug Discovery.http://medicinalchemistryproject. info/Discovery.html
73. Pearson L, Mihali T, Moffitt M, Kellmann R, Neilan B. (2010) On the chemistry, toxicology and genetics of the cyanobacterial toxins, microcystin, nodularin, saxitoxin and cylindrospermopsin.Marine Drugs, 8, 1650-1680.
74. Jensen PR, Williams PG, Oh DC, Zeigler L, Fenical W. (2007) Species-specific secondary metabolite production in marine actinomycetes of the genus Salinispora. Applied Environmental Microbiology, 73, 1146-1152.
75. Thornburg CC, Zabriskie TM, McPhail KL. (2010) Deep-sea hydrothermal vents: potential hot spots for natural products discovery. Journal of Natural Products, 73, 489-499.
76. Fujiwara S. (2002) Extremophiles: developments of their special functions and potential resources. Journal of Biosciences and Bioengineering, 94, 518-525.
77. Kroiss J, Kaltenpoth M, Schneider B, Schwinger MG, Hertweck C, Maddula RK, Strohm E, Svatos A. (2010) Symbiotic Streptomycetes provide antibiotic combination prophylaxis for wasp offspring. Natural Chemical Biology, 6, 261-263.
78. Vézina C, Kudelski A, Sehgal SN. (1975). "Rapamycin (AY-22, 989), a new antifungal antibiotic". Journal of Antibiotic, 28, 721-6
79. Lihao M, Royce M, Benjamin HBK, Mikael E, Ny S, Craig MC. (1999) Epoxomicin, a potent and selectiveproteasome inhibitor, exhibits in vivo antiinflammatory activity. Proceedings of the National Academy of Science USA, 96, 10403-10408.
80. Drug bank: Open data drug and drug target database http://www.drugbank.ca/drugs/DB00694
81. Drug bank: Open data drug and drug target database http://www.drugbank.ca/drugs/DB00997
82. Drug bank: Open data drug and drug target database http://www.drugbank.ca/drugs/DB00445
83. Drug bank: Open data drug and drug target database http://www.drugbank.ca/drugs/DB01177
84. Medkoo Biosciences. http://www.medkoo.com/Anticancer-trials/Annamycin.htm.
85. Study of liposomal annamycin in patients with refractory or relapsed acute lymphocytic leukemia. http://www.clinicaltrials.gov/ct2/show/NCT00271063
86. Treatment virtual trials. http://www.virtualtrials.com/braintreatments.cfm
87. Bigioni M, Benzo A, Irrissuto C, Lopez G, Curatella B, Maggi CA, Manzini S, Crea A, Caroli S, Cubadda F, Binaschi M. (2008) Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.Cancer Chemotherapy Pharmacology, 62, 621-629.
88. Bellarosa D, Binaschi M, Maggi CA, Goso C. (2005) Sabarubicin-(MEN 10755) and paclitaxel show different kinetics in nuclear factor-kappaB (NF-kB) activation: effect of parthenolide on their cytotoxicity.Anti-cancer Research, 25, 2119-2128.
89. Mazzini S, Scaglioni L, Animati F, Mondelli R. (2010) Interaction between double helix DNA fragments and the new antitumor agent sabarubicin Men10755. Bioorganic and Medicinal Chemistry, 18, 1497-1506.
90. Caponigro F, Willemse P, Sorio R, Floquet A, van Belle S, Demol J, Tambaro R, Comandini A, Capriati A, Adank S, Wanders J. (2005) A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer.Investigational New Drugs, 23, 85-89.
91. Cristina G, Maria AS, Dario B, Marina C, Aurelio M, Luigi Q, Maura F, Massimo B. (2006) Nemorubicin: A doxorubicin-like structure with a novel mechanism of action different from anthracyclines. Proceedings for American Association for Cancer Research, 47, Abstract #3845.
92. Francesco Izzo, Thomas JV, Gennaro GC, Mark RM, Juan WV, Renate H, Cosmo DG, Marcella M, Anna P, Mariangela M, Cristina D, Francesco F. (2013) Phase II trial of nemorubicin hydrochloride (N) in combination with cisplatin (cDDP) administered by intra-hepatic artery (IHA) in patients (pts) with hepatocellular carcinoma (HCC): Final results. Journal. Clinical Oncology, 31, suppl; abstr e15061.
93. Drug bank: Open data drug and drug target database http://www.drugbank.ca/drugs/DB00385.
94. Drug bank: Open data drug and drug target database http://www.drugbank. ca/drugs/DB00290.
95. Drug bank: Open data drug and drug target database http://www.drugbank.ca/drugs/DB00385.
96. Drug bank: Open data drug and drug target database http://www.drugbank.ca/drugs/DB00970.
97. Drug bank: Open data drug and drug target database http://www.drugbank.ca/drugs/DB00305.
98. Parijat M, Dipak D. (2011) Effect of DNA Groove Binder Distamycin A upon Chromatin Structure. PLoS ONE, 6, e26486.
99. 4.Journal of Nucleic Acids, Volume 2010 (2010), Article ID 247137, 7 pages.
100. Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME, Sugarman S, Ma W, Patil S, Norton L, Hannah AL, Hudis C. (2011) HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clinical Cancer Research, 17, 5132-5139.
101. Katragadda U, Fan W, Wang Y, Teng Q, Tan C. (2013) Combined delivery of paclitaxel and tanespimycin via micellar nanocarriers: pharmacokinetics, efficacy and metabolomic analysis. PLoS One, 8, e58619.
102. Pacey S, Wilson RH, Walto M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, Peachey H, Aherne W, de Bono JS, Raynaud F, Workman P, Judson I. (2011) A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clinical Cancer Research, 17, 1561-1570.
103. Pipeline: RetaspimycinHCl (IPI-504).http://www.infi.com/product-candidates-pipeline-ipi-504.asp(ip1-504)
104. Phase 1b/2 Study of RetaspimycinHCl (IPI-504) in Combination with Everolimus in KRAS Mutant Non-small Cell Lung Cancer. http://www.clinicaltrials. gov/ct2/show/NCT01427946
105. Portugal J. (2003) Chartreusin, elsamicin A and related anticancer antibiotics. Current Medicinal Chemistry. Anti-cancer agents, 3, 411-420.
106. Lamks V, Veitch JA, Forenza S, Combs CM, Colson L.(1989) Biosynthesis of elsamicin A, a novel antitumour antibiotic. Journal of Natural Products, 52, 1015-1021.
107. Asai G, Yamamato N, Toi M, Shin E, Nishiyama K, Sekine T, Nomura Y, Takashima S, Kimura M, Tominaga T. (2002) Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast. Cancer Chemotherapy and Pharmacology, 49, 468-472.
108. Omura S, Iwai Y, Hirano A, Nakagawa A, Awaya J, Tsuchiya H, Takahashi Y, Masuma R. (1977) A new alkaloid AM-2282 of Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization. Journal of Antibiotics (Tokyo), 30, 275-282.
109. Tamaoki T, Nomot, H, Takahashi I, Kato Y, Morimoto M, Tomita F. (1986) Staurosporine, a potent inhibitor of phospholipid/Ca++ dependent protein kinase. Biochemical and Biophysical Research Communication, 135, 397-402.
110. Yamada S, Hirota K, Chida K, Kuroki T. (1988) Inhibition of phorbol ester-caused induction of ornithine decarboxylase and tumor promotion in mouse skin by staurosporine, a potent inhibitor of protein kinase C. Biochemical and Biophysical Research Communication, 157, 9-15
111. Paula CJ, Diego VW, Elthon GF, Renata T, Manoel O De.M, Edilberto R da S, Tito M da C L, Norberto PL, Leticia VCL. (2012) Structure Elucidation and Anticancer Activity of 7-Oxostaurosporine Derivatives from the Brazilian Endemic Tunicate Eudistoma vannamei. Marine Drugs, 10, 1092-1102.
112. A Phase I Trial of UCN-01 and Prednisone in patients with refractory solid tumoursand lymphomas. http://ichgcp.net/clinical-trials registry/research/index/NCT00045500
113. http://newsroom.lilly.com/releasedetail.cfm? releaseid =763858
114. Adam DC, Catherine D, Alice HL, Sebastien L, Joel M, Robert H, Yanfeng W. (2012) Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers. Cancer Chemotherapy and Pharmacology, 69, 1255-1263.
115. Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, Cortes J, Kantarjian HM, DeAngelo DJ, Huntsman-Labed A, Dutreix C, del Corral A, Giles F. (2012) Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia, 26, 2061-2068.
116. Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J. (2010) Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. Journal of Clinical Oncology, 28, 4339-4345.
117. Daunorubicin, Cytarabine, and Midostaurin in treating patients with newly diagnosed acute myeloid leukemia. http://www.clinicaltrials.gov/ct2/show/NCT00651261
118. Novartis Phase III trial examining EPO906 (patupilone) for patients with advanced ovarian cancer failed to meet primary endpoint. http://ichgcp.net/clinical-trials-registry/research/index/NCT01093573
119. Rogalska A, Marczak A, Gajek A, Szwed M, Sliwihska A, Drzewoski J, Józwiak Z. (2013) Induction of apoptosis in human ovarian cancer cells by new anticancer compounds, epothilone A and B. Toxicology In Vitro, 27, 239-249.
120. http://www.novartis.com/newsroom/media-releases/en/2010/1419057.html
121. McMeekin S, Patel R, Verschraegen C, Celano P, Burke J, Plaxe S, Ghatage P, Giurescu M, Stredder C, Wang Y, Schmelter T. (2012) Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer. Brazilian Journal of Cancer, 106, 70-76.
122. Rustin G, Reed N, Jayson GC, Ledermann JA, Adams M, Perren T, Poole C, Lind M, Persic M, Essapen S, Gore M, Calvert H, Stredder C, Wagner A, Giurescu M, Kaye S. (2011) A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Annals of Oncology, 22, 2411-2416.
123. Beer TM, Smith DC, Hussain A, Alonso M, Wang JM, Giurescu KR, Wang Y. (2012) Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the department of defence prostate cancer clinical trials consortium. Brazilian Journal of Cancer, 107, 808-813.
124. Drug bank: Open data drug and drug target database http://www.drugbank.ca/drugs/DB04845
125. Drug bank: Open data drug and drug target database http://www.drugbank.ca/drugs/DB01873
126. Robert MB, Gregory DV. (2002) Epothilones: new tubulin polymerization agents in preclinical and clinical development. Drugs Future, 27, 1149-1163.
127. Arun KG, David DA. (2012) Enantioselective Total Synthesis of Pladienolide B: A Potent Spliceosome Inhibitor. Organic Letters, 14, 4730-4733.
128. Masao, Iwata et al. (2004) E7107, a new 7-urethane derivative of pladienolide D, displays curative effect against several human tumor xenografts. Proceedings of American Association for Cancer Research, 45.Abstract #2989
129. A Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid Tumours. Clinical Trials.gov Identifier: NCT00459823.
130. Folco EG, Coil KE, Reed R. (2011) The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region. Genes & Development, 25, 440-444.
131. Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F. (2008) Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opinion Investigational Drugs, 17, 1947-54.
132. Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJ. (2008)A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clinical Cancer Research, 14, 2756-2762.
133. Usama RA, Matthias S, Eman MO, Tanja S, Stephanie G, Helga S, Ute H. (2012) Antioxidant and Anti-Protease Activities of Diazepinomicin from the Sponge-Associated Mcromonospora Strain RV115. Marine Drugs, 10, 2208-2221.
134. Boufaied N, Wioland MA, Falardeau P, Gourdeau H. (2010) TLN-4601, a novel anticancer agent, inhibits Rassignaling post Rasprenylation and before MEK activationWioland MA, Falardeau P, Gourdeau H. Anti-cancer Drugs, 21, 543-552.
135. Campbell PM, Boufaied N, Fiordalisi JJ, Cox AD, Falardeau P, Der CJ, Gourdeau H. (2010) TLN-4601 suppresses growth and induces apoptosis of pancreatic carcinoma cells through inhibition of Ras-ERK MAPK signaling. Journal of Molecular Signaling, 5, 18-28.
136. Mason WP, Belanger K, Nicholas G, Vallières I, Mathieu D, Kavan P, Desjardins A, Omuro A, Reymond D. (2012) A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression. Journal of Neurooncology, 107, 343-349.
137. Robert MQ, Shanks M, Roni ML, Nicholas AS, Daniel HK, Xinyu L, Eric JK A, Roni M L, Nicholas AS, Daniel H K, Xinyu L, Eric J K. (2013) Serratiamarcescens Pig Phomolog controls prodigiosin biosynthesis, swarming motility and haemolysis and is regulated by cAMP-CRP and HexS Shanks mail, Plos ONE, 8, e57634.
138. Bode HB, Bethe B, Höfs R, Zeek A. (2002) Big effects from small changes: possible ways to explore nature's chemical diversity. Chemistry and Chemical Biology, 3, 619-627.
139. Chin YW, Balunas MJ, Chai HB. (2006) Drug discovery from natural sources. The AAPS Journal, 8, 239-253.
140. Donadio S, Monicardini P, Alduina R, Mazzaa P, Chiocchini C, Cavaletti L, Sosio M, Puglia AM. (2002) Microbial technologies for the discovery of novel bioactive metabolites. Journal of Biotechnology, 99, 187-198.
141. Gunatilaka AAL. (2006) Natural products from plant-associated microorganisms: Distribution, structural diversity, bioactivity, and implications of their occurrence. Journal of Natural Products, 69, 509-526.
142. Mitchell AM, Strobel GA, Hess WM, Vargas PN, Ezra D. (2008) Muscodorcrispans, a novel endophyte from Anansananassoides in the Bolivian Amazon, Fungal Diversity, 31, 37-43.
143. Kock JLF, Strauss T, Pohl CH, Smith DP, Botes PJ, Pretorius EE, Tepeny T, Sebolai O, Botha A, Nigam S. (2001) Bioprospecting for novel oxylipins in fungi: the presence of 3-hydroxy oxylipins in Pilobolus. Antonie van Leeuwenhoek, 80, 93-99.
144. Misiek M, Hoffmeister D. (2007) Fungal genetics, genomics, and secondary metabolites in pharmaceutical sciences. Planta Medica, 73, 103-115.
145. Schneider P, Misiek M, Hoffmeister D. (2008) In vivo and in vitro production options for fungal secondary metabolites. Molecular Pharmacology, 5, 234-242.
146. Selim KA, El-Beih AA, AbdEl-Rahman TM2, El-Diwany AI. (2012)Biology of endophytic fungi. Current Research in Environmental and Applied Mycology, 2, 84-97.
147. Saleem M, Ali MS, Hussain S, Jabbar A, Ashraf M, Lee YS. (2007) Marine natural products of fungal origin. Natural Product Reports, 24, 1142-1152.
148. Birch AJ, Hussain SF. (1969) Studies in relation to biosynthesis. Part XXXVIII. A preliminary study of fumagillin. Journal of Chemical Society (C), 1473-1474.
149. Kruger EA, Figg WD. (2000) TNP-470: an angiogenesis inhibitor in clinical development for cancer. Expert Opinion in Investigational Drugs, 9, 1383-1396.
150. Bernsen HJJA, Rijken PFJW, Peters H, Bakker H, van der Kogel AJ.(1998)The effect of the anti-angiogenic agent TNP-470 on tumor growth, vascular area, vascular density and tumor perfusion of two different subcutaneously implanted human glioma xenografts (E98 and E106) in nude mice. Journal of Neuro Oncolology, 38, 51-57.
151. Angiogenesis backgrounder. http://www.news. harvard.edu/gazette/2004/02.26/01-tnp.html
152. Sang J S, Hei-Cheu J, Joong BA, Sun YR, Jae KR, Kyung SP, Dal-Hyun K, Chin K, Hyun CC. (2010) A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. Investigational New Drugs, 28, 650-658.
153. Kim EJ, Shin WH. (2005) General pharmacology of CKD-732, a new anticancer agent: effects on central nervous, cardiovascular, and respiratory system. Biological and Pharmaceutical Bulletin, 28, 217-223.
154. Lee HS, Choi WK, Son HJ, Lee SS, Kim JK, Ahn SK, Hong CI, Min HK, Kim M, Myung SW. (2004) Absorption, distribution, metabolism, and excretion of CKD-732, a novel antiangiogenic fumagillin derivative, in rats, mice, and dogs. Archives of Pharmacal Research, 27, 265-272.
155. Shin SJ, Ahn JB, Park KS, Lee YJ, Hong YS, Kim TW, Kim HR, Rha SY, Roh JK, Kim DH, Kim C, Chung HC. (2012) A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. Investigational New Drugs, 30, 672-680.
156. Thomas G, Paul A K, Kay CP, Laura KC, Gary M. (1996) MIsolation of IlludinS from the Mature Basidiocarp of Omphalotus Illudens, and Isolation of IlludinsS and M from the Fermentation Broth of Omphalotus Olearis. Natural Product Letters, 9, 87-95.
157. Hendrik G, Ietidal E M, Alexander P, Stefan K, Harald G, Gabriele MK. (2010) Fungal metabolites: structural diversity as incentivefor anticancer drug development. Phytochemistry Reviews, 9, 537-545.
158. Wang Y, Wiltshire T, Senft J, Wenger SL, Reed E, Wang W. (2006) Fanconianemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven. Molecular Cancer Therapeutics, 5, 3153-3161.
159. Elinoar S. (2008) Irofulven-Halloween Trick or a Beacon of Light. Medicinal mushrooms, Volume 1:1.
160. Russell J S, John AB, Mark SS, David S.M, Krishnansu ST, Carolyn YM, David W, McMeekin DS, Jacob R. (2010) A phase II evaluation of Irofulven (IND#55804, NSC#683863) as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group trial. International Journal of Gynecological Cancer, 20, 1137-1141.
161. Kanoh K, Kohno S, Asari T, Harada T, Katada J, Muramatsu M, Kawashima H, Sekiya H. (1997) Uno, I. (-)-Phenylahistin: a new mammalian cell cycle inhibitor produced by Aspergillus ustus. Bioorganic and Medicinal Chemistry Letters, 7, 2847-2852.
162. Millward M, Mainwaring P, Mita A, Federico K, Lloyd GK, Reddinger N, Nawrocki S, Mita M. (2012)Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel Spear MAMain waring P. Investigational New Drugs, 30, 1065-73.
163. Bertelsen LB, Shen YY, Nielsen T, Stødkilde-Jørgensen H, Lloyd GK, Siemann DW, Horsman MR. (2011) Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation. International Journal of Radiation Biology, 87, 1126-1134.
164. Mita MM, Spear MA, Yee LK, Mita AC, Heath EI, Papadopoulos KP, Federico KC, Reich SD, Romero O, Malburg L, Pilat M, Lloyd GK, Neuteboom ST, Cropp G, Ashton E, LoRusso PM. (2010) Phase 1 first-in-human trial of the vascular disrupting agent plinabulin (NPI-2358) in patients with solid tumors or lymphomas. Clinical Cancer Research, 16, 5892-5899.
165. Mita A C, Heist R S, Aren O, Mainwaring P N, Bazhenova L, Gadgeel SM, Blum, R. H, Polikoff J, Biswas J, Spear MA. (2010) Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 28, 15-16.
166. Bergmann W, Feeney RJ. (1951) Contributions to the study of marine products. XXXII. The nucleosides of sponges. Journal of Organic Chemistry, 16, 981-987.
167. Bergmann W, Burke DC. (1955) Contributions to the study of marine products. XXXIX. The nucleosides of sponges. III. Spongothymadine and spongouridine. Journal of Organic Chemistry, 20, 1501-1507.
168. Bergmann W, Stempien MF. (1957) Contributions to the study of marine products. Journal of Organic Chemistry, 22, 1575-1577.
169. Suckling CJ. (1991) Chemical approaches to the discovery of new drugs. Science Programing, 75, 323-59.
170. Jensen PR, Fenical W. (2000) Marine microorganism and drug discovery: Current status and future potential. In: Fusetani N(ed.) Drugs from the Sea. Karger, Basel, 6-29.
171. Newman DJ, Cragg GM. (2004) Advanced preclinical and clinical trials of natural products and related compounds from marine sources. Current Medicinal Chemistry, 11, 1693-1713.
172. Newman DJ, Cragg GM. (2004) Marine natural products and related compounds in clinical and advanced preclinical trials. Journal of Natural Products, 67, 1216-38.
173. Taraboletti G, Poli M, Dossi R. (2004) Antiangiogenic activity of aplidine, a new agent of marine origin. Brazilian Journal of Cancer, 90, 2418-2424.
174. Wang WS, Tzeng CH, Chiou TJ, Liu JH, Hsieh RK, Yen CC, Chen PM. (1997) High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma. Japanese Journal of Clinical Oncology, 27, 154-157.
175. Mayer AMS, Glaser KB, Cuevas C, Jacobs RS, Kem W, Little RD, McIntosh JM, Newman DJ, Potts BC, Shuster DE. (2010) The odyssey of marine pharmaceuticals: A current pipeline perspective. Trends in Pharmacological Science, 31, 255-265.
176. Abraham I, Sayed El K, Chen ZS, Guo H. (2012) Current status on marine products with reversal effect on cancer multidrug resistance. Marine Drugs, 10, 2312-2321.
177. Huyck TK, Gradishar W, Manuguid F, Kirkpatrick P. (2011) Eribulin mesylate. Natural Reviews Drug Discovery, 10, 173-174.
178. Drug bank: Open data drug and drug target database. http://www.drugbank.ca/drugs/DB08870.
179. Christos V, Andres FT. (2012) Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.Therapeutics Advances in Hematology, 3, 209-225.
180. Boopathy NS, Kathiresan K. (2010) Anticancer drugs from marine flora: an overview. Journal of Oncology, 214186, 1-18.
181. Luesch H, Chanda SK, Raya RM, De Jesus PD, Orth AP, Walker JR, Izpisúa Belmonte JC, Schultz PG. (2006) A functional genomics approach to the mode of action of apratoxin A. Nature Chemical Biology, 2, 158-567.
182. Rana M, Hendrik L. (2011) Marine natural products: new wave of drugs. Future Medicinal Chemistry, 3, 1475-1489.
183. Jiyong H, Hendrik L. (2012) Largazole: From discovery to broad-spectrum therapy. Natural Product Reports, 29, 449-456.
184. Rinehart K, Gloer JB, Cook JC. (1981) Structures of didemnins, antiviral and cytotoxic depsipeptides from a Caribbean tunicate. Journal of American Chemical Society, 103, 1857-1859.
185. Nuijen B, Bouma M, Manada C, Jimeno JM, Schellens JHM, Bult A, Beijnen JH. (2000) Pharmaceutical development of anticancer agents derived from marine sources. Anti-Cancer Drugs, 11, 793-811.
186. Pitot HC, McElroy EA Jr, Reid JM. (1999) Phase I trial of dolastatin-10 (NSC 37612in patients with advanced solid tumors. Clinical Cancer Research, 5, 525-31.
187. Vaishampayan U, Glode M, Du W, Kraft A, Hudes G, Wright J, Hussain M. (2000) Phase II Study of Dolastatin 10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clinical Cancer Research, 6, 4205-4208
188. Hoffman M, Blessing J, Lentz S. (2003) A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology, 89, 95-8.
189. Simmons TL, Eric A, Kerry M, Patricia F, William HG. (2005) Marine natural products as anticancer drugs. Molecular Cancer Therapeutics, 4, 333-342.
190. Kerbrat P, Dieras V, Pavlidis N, Ravaud A, Wanders J, Fumoleau P. (2003) Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer. European Journal of Cancer, 39, 317-320.
191. Marks R, Graham D, Sloan J et al. (2003) A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer. American Journal of Clinical Oncology, 26, 336-337.
192. Smyth J, Boneterre ME, Schellens J, Calvert H, Greim G, Wanders J, Hanauske A. (2001) Activity of the dolastatin analogue, LU103793, in malignant melanoma. Annals of Oncology, 12, 509-511.
193. Lu C, Lee JJ, Komaki R, Herbst RS, Feng L, Evans WK, Choy H, Desjardins P, Esparaz BT, Truong MT, Saxman S, Kelaghan J, Bleyer A, Fisch MJ. (2010) Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. Journal of National Cancer Institute, 102, 859-865.
194. Dumez H, Gall H, Capdeville R, Dutreix C, van Oosterom AT, Giaccone G. (2007) A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer.Anti-cancer Drugs, 18, 219-225.
195. Cernaianu G, Frank S, Erbstösser K, Leonhardt S, Cross M, McIvor Z, Scholz G, Dansranjavin T, Celik I, Tannapfel A, Wittekind C, Troebs RB, Rothe K, Bennek J, Hauss J, Witzigmann H. (2006)TNP-470 fails to block the onset of angiogenesis and early tumor establishment in an intravital minimal disease model. International Journal of Colorectal Disease, 21, 143-154.
196. Panda D, DeLuca K, Williams D, Jordan MA, Wilson L. (1998) Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends. Proceedings of National Academy of Science USA, 95, 9313-9318.
197. Lisa D, Robert LF, Tamara N Do, Geoffrey PD, Daniel PP. (2002) The novel anti-microtubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells. Clinical Cancer Research, 8, 3922-3932.
198. Edelman MJ, Gandara DR, Hausner P, Israel V, Thornton D, De Santo J, Doyle LA. (2003) Phase 2 study of cryptophysin 52 in patients previously treated with platinum based chemotherapy for advanced NSCLC. Lung cancer, 39, 197-199.
199. Stevenson JP, Sun W, Gallagher M, Johnson R, Vaughn D, Schuchter L, Algazy K, Hahn S, Enas N, Ellis D, Thornton D, O'Dwyer PJ. (2002) Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 scheduleevery 21 days. Clinical Cancer Research, 8, 2524-2529.
200. Sessa C, Weigang-Kohler K, Pagani O, Greim G, Mora O, De Pas T, Burgess M, Weimer I, Johnson R. (2002) Phase I and pharmacological studies of the cryptophycinanalogue LY355703 administered on a single intermittent or weekly schedule. European Journal of Cancer, 38, 2388-2396.
201. D'Agostino G, Campo JD, Mellado B, Izquierdo MA, Minarik T, Cirri L, Marini L, Perez-Gracia JL, Scambia GA. (2006) A multicenter phase II study of the cryptophycinanalog LY355703 in patients with platinum-resistant ovarian cancer. International Journal of Gynaecological Cancer, 16, 71-76.
202. Liang J, Moore RE, Maher ED, Munroe JE, Al-awar RS, Hay DA, Varie DL, Zhang TY, Aikins JA, Mastinelli MJ, Shih C, Ray JE, Gibson LL, Vasudevan V, Palin L, White K, Kushner J, Simpson C, Pugh S, Corbett TH. (2005) Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors. Investigational New Drugs, 23, 213-224.
203. Jones RJ, Sharkis SJ, Miller CB, Rowinsky EK, Burke PJ, May WS. (1990) Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro. Blood, 75, 1319-1323.
204. Kortmansky J, Schwartz G K. (2003) Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Investigation, 21, 924-936.
205. Tourneau Le C, Faivre S, Ciruelos E, Domínguez MJ, López-Martín JA, Izquierdo MA, Jimeno J, Raymond E. (2010) Reports of clinical benefit of plitidepsin (Aplidine), a new marine-derived anticancer agent, in patients with advanced medullary thyroid carcinoma. American Journal of Clinical Oncology, 33, 132-136.
206. Baudin E, Droz JP, Paz-Ares L, van Oosterom AT, Cullell-Young M, Schlumberger M. (2010) Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma. American Journal of Clinical Oncology, 33, 83-8.
207. Randomized, multicenter, open-label, phase III study of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. http://clinresearch.info/research/index/NCT01102426.
208. Vincent R, Dolores C, Christophe F, Emanuele Z, Reyes A, Javier B, Christian G, Gilles S, Alessandro MG, Henry G, Carmen K, Claudia C, Sergio S, Sonia E, Bernardo de M, Martin C-Y, Franco C. (2013) Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-hodgkin's lymphoma. Haematology, 98, 357-363.
209. Orphan drugs. http://www.checkorphan.org.
210. Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W. (2003) Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angewandte Chemie International Edition, 42, 355-357.
211. William F, Paul RJ, Michael AP, Kin SL, Kenneth GL, Barbara CP. (2009) Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorganic and Medicinal Chemistry, 17, 2175-2180.
212. Amanda O, Jeffrey W, Brett W, Rama RM, Venkat RM, Katherine M, Ta-Hsiang, Michael A. P, G. Kenneth L, Barbara C. P, Salvatore JE, Saskia TCN, Bruno HH. (2011) Proteasome regulator marizomib (NPI-0052) exhibits prolonged inhibition, attenuated efflux, and greater cytotoxicity than its reversible analogs. Journal of Pharmacology and Experimental Therapeutics, 337, 479-486.
213. Tadeusz F M, Doralyn S D, Sarah LL, Jonel PS. (2009) Drug development from marine natural products. Nature Reviews Drug Discovery, 8, 69-85.
214. Phase II clinical trial to begin: squalamine eye drops for wet macular degeneration.http://www.visionaware.org/blog.aspx?BlogID=9&BlogEntryID=482.
215. Revill P, Mealy N, Serradell N, Bolos J, Rosa E. (2007) Panobinostat. Drugs Future, 32, 315-322.
216. http://www.novartisoncology.com/research-innovation/pipeline.jsp.
217. Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM. (2012) Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. Journal of Clinical Oncology, 30, 2197-203.
218. Mascarenhas J, Lu M, Li T, Petersen B, Hochman T, Najfeld V, Goldberg JD, Hoffman RA. (2013) phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Brazilian Journal of Haematology, 161, 68-75.
219. Frincke JM, Faulkner DJ. (1982) Antimicrobial metabolites of the sponge Reniera sp. Journal of American Chemical Society, 104, 265-269.
220. Davidson BS, Renieramycin G.(1992) A new alkaloid from the sponge Xestospongia caycedoi. Tetrahedron Letters, 33, 3721-3724.
221. Fontana A, Cavaliere P, Wahidulla S, Naik CG, Cimino G. (2000) A new antitumourisoquinoline alkaloid from the marine nudibranch Jorunna funebris. Tetrahedron, 56, 7305-7308
222. Capdevila J, Clive S, Casado E, Michie C, Piera A, Sicart E. (2013) A phase I pharmacokinetic study of PM00104 (Zalypsis(®)) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors. Cancer Chemotherapy Pharmacology, 71, 1247-1254.
223. González SM, Valenzuela B, Pérez-Ruixo C, Fernández TC, Miguel-Lillo B, Soto-Matos A, Pérez-Ruixo J. (2012) Population pharmacokinetic-pharmacodynamic analysis of neutropenia in cancer patients receiving PM00104. Journal of Clinical Pharmacokinetics, 51, 751-764.
224. Rinehart K, Holt TG, Fregeau NL, Stroh JG, Keifer PA, Sun F. (1990) Ecteinascidins 729, 743, 745, 759A, 759B and 770: potent antitumor agents from the Caribean tunicate Ecteinascidia turbinate. Journal of Organic Chemistry, 55, 4512-4515.
225. Manzanares I, Cuevas C, Garcia-Nieto R, Marco E, Gago F. (2001) Advances in the chemistry and pharmacology of ecteinascidins, a promising new class of anti-cancer agents. Currunt Medicinal Chemistry Anti-cancer Agents, 1, 257-276.
226. Leal JFM, Martínez-Díez M, García-Hernández V, Moneo V, Domingo A, Bueren-Calabuig JA, Negri A, Gago F, Guillén-Navarro MJ, Avilés P, Cuevas C, García-Fernández LF, Galmarini CM. (2010) PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Brazilian Journal of Pharmacology, 161, 1099-1110.
227. A phase II clinical trial of PM01183 in BRCA 1/2-associated or unselected metastatic breast cancer. http//www.clinical trials gov NCT01525589.
228. Galina K, Karen TD, Murray JT, Hongsheng C, Junke Liu, Joanne PM, Shawn ERS, Mark R S, Hu Y, Boris MS, Christina JS, Veronique M, Ye. Y, Edward MS, Silvio C, Francis G F, James JK, Bruce AL. (2009) Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin.Molecular Cancer Therapeutics, 8, 2852-2860.
229. Caio M R, Soley B, Jessica M I, Luis R, Aurea M. F, Annapoorna F, Eric H. R, Elizabeth A. P, Antoinette R. T, Antonio L, Naseem Z. (2012) A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors. Cancer, 118, 4262-4270.
230. Weterman MA, Ajubi N, van Dinter IM, Degen WG, van Muijen GN, Ruitter DJ. (1995) Bloemers, H.P.nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. International Journal of Cancer, 60, 73-81.
231. Final data from celldextherapeutic's cdx-011 phase 2 study in metastatic breast cancer supports overall survival benefit in patients with high gpnmb expression.http://ir.celldextherapeutics.com/releasedetail.cfm?ReleaseID=725688.
232. http://www.fiercebiotech.com
233. http://oncozine.com/profiles/blogs/phase-i-trial-starts-with.
234. http://www.centerwatch.com
235. Seattle Genetics: advancing antibody-drug conjugates for cancer. http://www.seattlegenetics.com.
236. Zhou W, Zhu W-G. (2009) The changing face of HDAC inhibitor depsipeptide. Current Cancer Drug Targets, 9, 91-100.
237. Zhu WG, Lakshmanan RR, Beal MD, Otterson GA. (2001) DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase Inhibitors. Cancer Research, 61, 1327-1333.
238. Adachi M, Zhang Y, Zhao X, Minami T, Kawamura R, Hinoda Y, Imai K. (2004) Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamicacid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells. Clinical Cancer Research, 10, 3853-3862.
239. Chandra S, Bandopadhyay R, Kumar V, Chandra R. (2010) Acclimatization of tissue cultured plantlets: from laboratory to land. Biotechnology Letters, 32, 1191-1205.
240. Firáková S, Sturdíková M, Múcková M. (2007) Bioactive secondary metabolites produced by microorganisms associated with plants. Biologia, 62, 251-257.
241. Limsuwan S, Trip EN, Kouwenc TRHM, Piersmac S, Hiranrat A, Mahabusarakam W, Voravuthikunchai SP, Van Dijl JM, Kayser O. (2009) A new candidate as natural antibacterial drug from Rhodomyrtustomentosa. Phytomedicine, 16, 645-651.
242. Stierle AA, Strobel G, Stierle DB. (1993) Taxol and taxane production by Taxomycesandreanae, an endophytic fungus of pacific yew. Science, 260, 214-216.
243. Ge J, Ping W, Zhou D. (2004) Characterization of a new species of taxol-producing fungus. Nature and Science, 2, 85-88.
244. Yuan J, Jian-Nan B, Bing Y, Xu-Dong Z. (2006) Taxol-producing fungi: a new approach to industrial production of taxol. Chinese Journal of Biotechnology, 22, 1-6.
245. Kusari S, Zuhlke S, Spiteller M. (2009) An endophytic fungus from Camptotheca acuminata that produces camptothecin and analogues. Journal of Natural Products, 72, 2-7.
246. Touseef A, Musarat A, Sharma PR, Puri SC, Hanan MY, Areej MA, Qazi GN. (2012) Effect of precursors feeding and media manipulation on production of novel anticancer pro-drug camptothecin from endophytic fungus. Brazilian Journal of Microbiology, 43, 1476-1489.
247. Kharwar RN, Verma VC, Strobel G, Ezra D. (2008) The endophytic fungal complex of Catharanthus roseus (L.) G. Don. Current Science, 95, 228-233.
248. Eyberger AL, Dondapati R, Porter JR. (2006) Endophyte fungal isolates from Podophyllum peltatum produces podophyllotoxin. Journal of Natural Products, 69, 1121-1124.